Over 150 Total Lots Up For Auction at Two Locations - PA 05/15, NY 05/20

Dr. Mark Rosenblum

Former neurosurgery chairman of Henry Ford Health System joins NICO Corporation board of directors
May 31, 2018
Alzheimers/Neurology
Dr. Mark Rosenblum
INDIANAPOLIS, May 29, 2018 /PRNewswire/ -- Highly regarded neurosurgeon, Mark Rosenblum, MD, has joined the Board of Directors of Indianapolis-based medical device company, NICO Corporation. Dr. Rosenblum has authored 7 books and more than 250 articles and chapters relating to neurosurgery and neuroscience and has received many awards for his research and clinical work, including from the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) for life-long contributions to neuro-oncology.

NICO President and CEO, Jim Pearson, said Dr. Rosenblum's expertise and history in delivering innovative surgical approaches and improved clinical outcomes in neurosurgery perfectly aligns with the company's growing market adoption of its technologies used in minimally disruptive trans-sulcal surgical approaches. His executive healthcare experience also adds strength to defining the tangible economic benefits that lowering patient deficits has for hospitals.

"NICO is at a pivotal time in its product innovation and growth history," Pearson said. "Adding experts like Dr. Rosenblum, who delivered the plenary address on the future of neurosurgery at the 2018 AANS, complements our Board and is a timely addition as we continue our cadence with market penetration, product innovation and growth outside U.S. borders."
stats
DOTmed text ad

Your Trusted Source for Sony Medical Displays, Printers & More!

Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.

stats
Dr. Rosenblum currently is Chairman Emeritus of the Department of Neurosurgery in the Henry Ford Health System (HFHS), where he expanded the department over 22 years from four surgeons to 32 physicians and scientists. He also founded and served as a co-director of the nationally recognized Hermelin Brain Tumor Center and HFHS Neurosciences Institute. As a physician executive, he has focused on team building and integration, as well as technology development and process innovation.

"I am very impressed by both the goals of NICO and their leadership," said Dr. Rosenblum. "The focus of obtaining scientific evidence and promoting safe approaches to brain disorders is unique, in my mind.

"I look forward to helping NICO even better understand diseases of the brain and associated surgical considerations through the eyes of a neurosurgeon," he said. "I'm also interested in helping develop even more advanced tools to improve clinical care and patient outcomes."

Dr. Rosenblum obtained his B.S. at Rensselaer Polytechnic Institute (1965), M.D. at New York Medical College (1969), Medical Internship at the University of Michigan (1970), Staff Associate at the National Cancer Institute (NCI) (1972), Surgical Residency at the University of California, Los Angeles (1973) and Neurosurgery Residency at the University of California, San Francisco (UCSF) (1979). At UCSF he helped develop its world-leading Brain Tumor Research Center, became Professor of Neurosurgery, and was continuously funded by the NCI and American Cancer Society for early research on cancer stem cells. He founded and chaired the Section on Tumors of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS), the largest specialty organization of neuro-oncology in his field.

You Must Be Logged In To Post A Comment

 

advertisement

Alzheimers/Neurology Homepage

Long-term gantenerumab treatment shows potential for delaying Alzheimer’s symptoms
Findings suggest potential benefit from sustained amyloid removal
Achieving moonshots in neurotechnology: Three strategies to break paradigms and expand horizons
Insights from Ruthi Aladjem, Corundum Neuroscience and Sharena Rice, Sanmai Technologies PBC
Lantheus to acquire Life Molecular Imaging for up to $750 million, expanding Alzheimer's PET portfolio
Neuraceq is an F-18 PET imaging agent approved for detecting beta-amyloid plaques
Philips expands neurovascular therapy partnership with Sim&Cure
Streamlining brain aneurysm treatment through workflow efficiency and precision
Portable MR shows promise for Alzheimer’s disease diagnosis and monitoring
Researchers at MGH envision a future where cognitive assessments are more accessible
Philips and icometrix partner for AI-driven neurology imaging
Integrating icometrix’s FDA-cleared AI tools into Philips BlueSeal MR scanners
GE HealthCare gets FDA clearance for head-only 3T MR system
Offering enhanced capabilities for neurological, oncological, and psychiatric research
GE receives FDA clearance for its MIMneuro Centiloid scaling tool
It quantifies amyloid plaque in PET brain imaging
Researchers tout two-photon fluorescence microscope for brain imaging
Promising tool for studying neural dynamics and neurological diseases in real time
GE unveils head-only 3T MR scanner
SIGNA MAGNUS is for neurological and psychiatric research